Leerink Partnrs Has Negative Outlook of VKTX FY2025 Earnings
Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Tourmaline Bio FY2024 EPS Forecast Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
T-knife Therapeutics to Participate in Two Investor Conferences in March
SAN FRANCISCO and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Biohaven Ltd. (BHVN – ...
Investment Banker Cleared to Seek Multi-Million Bonuses Against Former Boston Employer
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
CVS Health's turnaround efforts in focus amid record-high medical costs
CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...
AbbVie and Xilio partner for tumor-activated therapies
NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...
Q4 2024 Gilead Sciences Inc Earnings Call
Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer ...